Tumor-infiltrating lymphocytes (TIL) were analyzed by 16-color multi-parametric flow cytometry using the following antibodies: BUV737 anti-CD3 (17A2), Alexa Fluor 700 anti-Granzyme B (GB11), BV605 anti-CD11c (HL3), APC-Cy7 anti-CD11b (M1/70), anti-mouse CD16/32 (2.4G2, mouse Fc-block) from BD Bioscience (San Jose, CA), BV650 anti-CD8 (53–6.7), APC anti-CTLA-4 (UC10-4B9), PerCP-ef710 anti-Lag3 (C9B7W), PE-Cy7 anti-PD-1 (RMP1–30), BV711 anti-PD-L1 (10F.9G2), PE-Cy5 anti-F4/80 (BM8) from Biolegend (San Diego, CA), Alexa Fluor 488 anti-FoxP3 (150D/E4) and e450 anti-Gr-1 (RB6-8C5) from eBioscience (Waltham, MA). The following antibodies for in vivo administration were purchased from BioXcell (West Lebanon, NH) and used at the concentrations shown: α-PD-1 (RMP1–14 at 250 μg per dose), α-CTLA-4 (9H10 at 100 μg per dose) and α-Lag-3 (C9B7W at 200 μg per dose). The STING agonist ML-RR-S2 CDA (ADU-S100) was procured from MedChemExpress (Monmouth Junction, NJ). For fluorescence immunohistochemistry, rabbit monoclonal anti-mouse PD-L1 antibody was purchased from Abcam (Cambridge, MA) and chicken anti-rabbit IgG cross-absorbed antibody Alexa Fluor 594 conjugate from Invitrogen (Carlsbad, CA).
α pd 1 rmp1 14
Manufactured by BioXCell
Sourced in United States
α-PD-1 (RMP1-14) is an anti-PD-1 monoclonal antibody. It binds to the programmed cell death-1 (PD-1) receptor, which is expressed on the surface of activated T cells.
Automatically generated - may contain errors
Lab products found in correlation
α ctla 4 9h10, by BioXCell (2 mentions)
αpd l1 10f 9g2, by BioXCell (2 mentions)
Ml rr s2 cda adu s100, by MedChemExpress (1 mentions)
Alexa fluor 594 conjugate, by Thermo Fisher Scientific (1 mentions)
αctla 4 clone 9d9, by BioXCell (1 mentions)
α cd4, by BioXCell (1 mentions)
αpd l1, by BioXCell (1 mentions)
α ox40, by BioXCell (1 mentions)
α ifn γ, by BioXCell (1 mentions)
C57bl 6 mice, by Jackson ImmunoResearch (1 mentions)
6 protocols using α pd 1 rmp1 14
1
Multiparametric Flow Cytometry for TIL
2
PD-1/PD-L1 Targeting Antibody Labeling
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
α-PD-1 (RMP1-14) and α-PD-L1 (10F.9G2) were purchased from BioXCell and conjugated with the metal chelator S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA), as described before 28 (link). Radioactive 64Cu (Eberhard Karls University, Tübingen, Germany) was used for mAb loading as described before 28 (link). In vivo antibody binding specificity was tested with the same mAbs labeled with AlexaFluor 680 (AF680-SAIVI Kit, Invitrogen) according to the manufacturer's instructions.
3
Combination Immunotherapy for B16-OVA Melanoma
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
C57BL/6 mice were given 5 × 105 B16-OVA cells s.c. in the dorsal flank; 3, 8, and 18 days later 20 μg MS-OVA was injected s.c. at the base of the tail away from the tumor site. A total of 100 μg α-CTLA-4, Clone 9D9 (BioXcell, West Lebanon, NH, USA) was given s.c. alongside the archaeosome treatment (days 3, 8, and 18). A total of 250 μg each of α-PD-1, RMP1-14 (BioXcell, West Lebanon, NH, USA) and α-PD-L1, 10F.9G2 (BioXcell, West Lebanon, NH, USA) was given i.p. on days 9, 12, 15, and 18. Rationale for timing and injection site choice for checkpoint inhibitors: α-CTLA-4 was given alongside the archaeosome vaccine s.c. so that it would drain to the same lymph nodes and act on the same CD8+ T cells that were being activated by the vaccine. α-PD-1 and α-PD-L1 were given in parallel i.p. at the time when tumors were thought to be growing so they could systemically act on augmenting CD8+ T cells responses to the tumor.
4
Studying Malaria Immune Modulation in Mice
5
Checkpoint Blockade and Peptide Therapy in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Mice were treated intraperitoneally with αPD-1 (RMP1-14, BioXcell, Lebanon, NH, USA; 200 μg per dose), αCTLA-4 (9H10, BioXcell; 200 μg per dose), and mC4BPA peptides consisting of 30 or 54 amino acids (Toray Research Center, Tokyo, Japan; 50 μg of 30 amino acids or 100 μg of 54 amino acids). Mouse IgG2a (Agilent; 200 μg) was used as an isotope control. All antibodies were endotoxin-free. Pharmaceutical grade Gem (Yakult Pharmaceutical, Tokyo, Japan) and nab-paclitaxel (Taiho Pharmaceutical, Tokyo, Japan) powders were purchased from Chiba University Hospital and resuspended in sterile normal saline at 40 mg/mL and 5 mg/mL, respectively. The drugs were administered by intraperitoneal injection at a dose of 120 mg/kg diluted in PBS.
6
Multivalent Nanoparticle Vaccine Efficacy
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
C57/Bl6J mice were injected subcutaneously at the
base of the tail on days 0, 7, and 14 with indicated formulations.
For studies with OVAp, NP-Pep/cGAMP/MPLA(1:4) contained 50 μg
of OVAp, 0.08 μg of cGAMP, and 0.8 μg of MPLA. For studies
with MC38 neoantigens, NP-Pep/cGAMP/MPLA(1:4) contained 25 μg
of Reps1, 25 μg of Adpgk, 0.08 μg of cGAMP, and 0.8 μg
of MPLA. On days 1, 4, 8, 11, 15, and 18, mice were administered 100
μg of αPD-1 (RMP1–14, BioXCell) intraperitoneally
for indicated studies. On day 21, the mice were euthanized to evaluate
the CD8+ T cell response in the spleen. Spleens were harvested
and mechanically disrupted into single cell suspensions in cRPMI by
forcing them through a 70 μm cell strainer. Red blood cells
were then lysed with ACK lysis buffer, and splenocytes were resuspended
in cRPMI and counted.
base of the tail on days 0, 7, and 14 with indicated formulations.
For studies with OVAp, NP-Pep/cGAMP/MPLA(1:4) contained 50 μg
of OVAp, 0.08 μg of cGAMP, and 0.8 μg of MPLA. For studies
with MC38 neoantigens, NP-Pep/cGAMP/MPLA(1:4) contained 25 μg
of Reps1, 25 μg of Adpgk, 0.08 μg of cGAMP, and 0.8 μg
of MPLA. On days 1, 4, 8, 11, 15, and 18, mice were administered 100
μg of αPD-1 (RMP1–14, BioXCell) intraperitoneally
for indicated studies. On day 21, the mice were euthanized to evaluate
the CD8+ T cell response in the spleen. Spleens were harvested
and mechanically disrupted into single cell suspensions in cRPMI by
forcing them through a 70 μm cell strainer. Red blood cells
were then lysed with ACK lysis buffer, and splenocytes were resuspended
in cRPMI and counted.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!